deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03461757

Trial in Adult Subjects With Acute Migraines

BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine

Sponsor: Pfizer

Conditions Migraine, With or Without Aura
Interventions Placebo Rimegepant
Updated 18 times since 2018 Last updated: Feb 14, 2023 Started: Feb 27, 2018 Primary completion: Oct 8, 2018 Completion: Oct 15, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Migraine, With or Without Aura and is currently completed. Pfizer leads this study, which shows 18 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Nov 2018 · 2 months · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jun 2019 · 6 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Jan 2023 · 24 months · monthly snapshot~Jan 2023 – ~Mar 2023 · 59 days · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Mar 2023 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2023 — Mar 2023 [monthly]

    Completed PHASE3

▶ Show 13 earlier versions

  1. Jan 2021 — Jan 2023 [monthly]

    Completed PHASE3

  2. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE3

  3. Feb 2020 — Apr 2020 [monthly]

    Completed PHASE3

  4. Nov 2019 — Feb 2020 [monthly]

    Completed PHASE3

  5. Sep 2019 — Nov 2019 [monthly]

    Completed PHASE3

  6. Jun 2019 — Sep 2019 [monthly]

    Completed PHASE3

  7. Dec 2018 — Jun 2019 [monthly]

    Completed PHASE3

  8. Nov 2018 — Dec 2018 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  9. Sep 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  10. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  11. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  12. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  13. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

    First recorded

Feb 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pfizer
Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Atlanta, United States , Augusta, United States , Austin, United States , Bellevue, United States , Berlin, United States , Boston, United States , Brooklyn, United States , Chalmette, United States , Charlottesville, United States and 54 more locations